文献速递浆细胞疾病

多发性骨髓瘤持续来那度胺维持治疗中微小残留病动态变化:单臂单中心2期试验

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2021-01-01

该单中心单臂2期试验纳入108例新诊断多发性骨髓瘤患者,予来那度胺10mg维持治疗至进展或不可耐受毒性(最多5年)。60个月无进展生存率为64%(95%CI 52-79),持续MRD阴性2年者无疾病进展记录,而MRD阴性丢失者进展风险显著增高。

核心结论

  • 系列MRD检测可动态评估疾病进展风险,MRD阴性丢失者应考虑早期干预研究。
  • 持续MRD阳性并非绝对不良结局,可能提示低水平疾病长期稳定。

研究设计与样本

  • 单中心、单臂、2期试验,纳入108例新诊断多发性骨髓瘤患者(100例可评估主要终点)。
  • 所有患者接受来那度胺10mg维持治疗,每28天周期用21天,直至进展或不可耐受毒性,最多5年。
  • MRD采用流式细胞术按IMWG标准检测,检测下限至少1×10^-5,基线及每年评估至最多5年。

主要发现

  • 19例(18%)发生血液学或非血液学严重不良事件;最常见≥3级不良事件为淋巴细胞减少48例(44%)和中性粒细胞减少47例(44%)。
  • 研究期间1例死亡(脓毒症和心力衰竭),被认为与研究药物无关。

关键数值与推荐

  • MRD阴性定义为按IMWG标准流式细胞术检测,检测下限至少1×10^-5。

临床怎么用

  • 对多发性骨髓瘤维持治疗患者可系列监测MRD以动态评估进展风险。
  • MRD阴性丢失者进展风险高,应考虑早期干预研究。
  • 持续MRD阳性并非均提示不良结局,可能表现为低水平疾病长期稳定。

局限性

  • 单中心、单臂设计,无对照臂。
  • 样本量有限,部分亚组分析例数较少(如MRD阴性丢失者仅10例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Background Lenalidomide maintenance improves progression-free survival for patients with multiple myeloma, although its optimal duration is unknown. Clearance of minimal residual disease (MRD) in the bone marrow results in superior outcomes, although its attainment or sustainment does not alter clinical decision-making. Studies that have evaluated MRD serially are limited in length. We therefore aimed to evaluate longitudinal changes in MRD-status (dynamics) and their association with progression-free survival in patients with multiple myeloma. METHODS: In this single-centre, single-arm, phase 2 study, we enrolled patients aged 18 years and older from the Memorial Sloan Kettering Cancer Center (New York, NY, USA) who had newly diagnosed multiple myeloma following unrestricted frontline therapy and an Eastern Cooperative Oncology Group Performance Status of 2 or lower, including patients who started maintenance before study enrolment. All participants received lenalidomide maintenance at 10 mg for 21 days of 28-day cycles until progression or unacceptable toxic effects for up to 5 years on protocol. The primary endpoint was progression-free survival at 60 months per protocol and key secondary endpoints were MRD rates after completion of the 12th, 24th, and 36th cycle of maintenance and the association between progression-free survival and annual measurement of MRD status. MRD was assessed from first-pull bone marrow aspirates at baseline and annually by flow cytometry per International Myeloma Working Group criteria, (limit of detection of at least 1 × 10-5) up to a maximum of 5 years. Patients who completed at least four cycles of treatment were included in the analysis of the primary endpoint, and patients who had completed at least one dose of treatment on protocol were assessable for secondary endpoints. The study was registered at ClinicalTrials.gov, NCT02538198, and is now closed to accrual. FINDINGS: Between Sept 8, 2015, and Jan 25, 2019, 108 patients (100 evaluable for the primary endpoint) were enrolled. Median follow-up was 40·7 months (95% CI 38·7-45·0). At 60 months, progression-free survival was 64% (95% CI 52-79). Median progression-free survival was unreached (95% CI unreached-unreached). MRD dynamics were assessed using 340 MRD assessments done over 5 years for 103 evaluable patients. Patients who sustained MRD negativity for 2 years (n=34) had no recorded disease progression at median 19·8 months (95% CI 15·8-22·3) past the 2-year maintenance landmark. By contrast, patients who lost their MRD-negative responses (n=10) were more likely to progress than those with sustained MRD negativity (HR infinite; p<0·0001) and those with persistent MRD positivity (HR 5·88, 95% CI 1·18-33·33; p=0·015) at the 2-year landmark. Haematological and non-haematological serious adverse events occurred in 19 patients (18%). The most common adverse events of grade 3 or worse were decreased lymphocyte count in 48 (44%) patients and decreased neutrophil count in 47 (44%) patients. One death occurred on study due to sepsis and heart failure and was considered unrelated to the study drug. INTERPRETATION: Serial measurements of MRD allow for dynamic assessment of risk for disease progression. Early intervention should be investigated for patients with loss of MRD negativity. Sustained MRD positivity is not categorically an unfavourable outcome and might portend prolonged stability of low-level disease. FUNDING: Memorial Sloan Kettering and Celgene.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Diamond B, Korde N, Lesokhin AM, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021. PMID: 34048681. doi:10.1016/S2352-3026(21)00130-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。